23andMe to Report Q1 FY2025 Financial Results

Rhea-AI Summary

23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has announced it will report its Q1 FY2025 financial results on Thursday, August 8, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the quarter's results and business progress.

Shareholders can access the webcast at https://investors.23andme.com/news-events/events-presentations. Additionally, 23andMe is using the Say Technologies platform to allow shareholders to submit and upvote questions for management before the earnings call. The Q&A platform will be open until 24 business hours before the call.

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s results and report on business progress.

The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional shareholders to submit and upvote questions to management in advance of the earnings conference call. Starting today, shareholders can submit questions by visiting https://app.saytechnologies.com/23andme-2025-q1. The Q&A platform will remain open until 24 business hours before the earnings call.

About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s strategy, financial position, financial projections, funding for continued operations, cash reserves, projected costs, database growth, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.

Contacts
Investor Relations Contact: Ian Cooney, ianc@23andme.com
Media Contact: press@23andMe.com  

FAQ

When will 23andMe (ME) report its Q1 FY2025 financial results?

23andMe (ME) will report its Q1 FY2025 financial results on Thursday, August 8, 2024, after the market closes.

How can I listen to 23andMe's (ME) Q1 FY2025 earnings conference call?

You can listen to 23andMe's (ME) Q1 FY2025 earnings conference call via webcast at 4:30 p.m. Eastern Time on August 8, 2024. The webcast can be accessed at https://investors.23andme.com/news-events/events-presentations.

How can shareholders submit questions for 23andMe's (ME) Q1 FY2025 earnings call?

Shareholders can submit and upvote questions for 23andMe's (ME) Q1 FY2025 earnings call using the Say Technologies platform at https://app.saytechnologies.com/23andme-2025-q1. The Q&A platform will be open until 24 business hours before the call.

What is the Nasdaq stock symbol for 23andMe?

The Nasdaq stock symbol for 23andMe is ME.